Skip to main content
Publish date:

Aldurazyme Approved in Japan

The drug is cleared as a treatment for a genetic disease.

BioMarin Pharmaceutical

(BMRN) - Get BioMarin Pharmaceutical Inc. Report

said Japan's Ministry of Health, Labor and Welfare granted marketing authorization for Aldurazyme as a treatment for the genetic disease mucopolysaccharidosis I.

Aldurazyme was developed by BioMarin and

TheStreet Recommends



and was approved in the U.S. and the European Union in 2003.

Mucopolysaccharidosis I is a progressive, debilitating and fatal genetic disease caused by an enzyme deficiency. Symptoms, which vary in severity, can include impaired cardiac and pulmonary function, delayed physical development, skeletal and joint deformities, reduced endurance, and in some cases, delayed mental function.

A majority of patients die before adulthood from complications of the disease.